Lorcaserin: Why Was This Weight Loss Drug Withdrawn?

Lorcaserin, sold under the brand name Belviq, was pulled from the U.S. market in February 2020 after extended follow-up from a large safety trial revealed a potential increase in cancer diagnoses among patients taking the drug. The FDA had approved lorcaserin in 2012 as a prescription weight-loss medication, making it one of the first new anti-obesity drugs in over a decade. Its withdrawal after less than eight years on the market is a case study in how post-approval safety monitoring can upend a drug that cleared every regulatory hurdle on the way in.

How Lorcaserin Worked

Lorcaserin was designed to target a specific serotonin receptor in the brain called 5-HT2C. Activating this receptor helps reduce appetite, so people feel full sooner and eat less. The drug lowered energy intake without increasing energy expenditure, meaning it curbed hunger rather than boosting metabolism.¹ This distinction mattered because earlier serotonin-based weight-loss drugs had activated multiple serotonin receptor subtypes, and that broader activity was linked to serious side effects. Lorcaserin’s selling point was selectivity: it was supposed to hit the appetite receptor without disturbing the others.

That selectivity was especially important given the shadow of fenfluramine and dexfenfluramine, the “fen-phen” drugs withdrawn in 1997 after causing heart valve damage. Those drugs activated the 5-HT2B receptor on heart valves, triggering abnormal tissue growth. Lorcaserin’s developers argued their drug was different because it preferentially activated 5-HT2C rather than 5-HT2B. The FDA took the heart valve concern seriously enough to require extensive echocardiographic monitoring during clinical trials.

What the Clinical Trials Showed

Lorcaserin’s approval was based primarily on two large Phase III trials, known as BLOOM and BLOSSOM. In pooled results, about 47% of patients taking lorcaserin lost at least 5% of their body weight over a year, compared with roughly 23% on placebo. The average weight loss was about 5.8% of body weight in the lorcaserin group versus 2.5% with placebo.² Around one in five lorcaserin patients lost 10% or more of their body weight, compared with fewer than one in ten on placebo.³ Beyond the scale, the trials also showed improvements in cholesterol, blood sugar markers, and quality-of-life scores.

These numbers met the FDA’s threshold for approval of weight-loss medications, which generally requires that at least 35% of patients on the drug lose 5% or more of their body weight and that the drug group significantly outperforms placebo. Lorcaserin cleared both bars. But the effect size was modest by today’s standards, especially compared with the newer GLP-1 receptor agonists that now dominate the obesity treatment landscape.

Clearing the Heart Valve Hurdle

The echocardiographic data from lorcaserin’s three Phase III trials turned out to be reassuring. Across more than 5,200 patients, rates of heart valve problems were essentially the same in the lorcaserin and placebo groups.⁴ This finding was a relief to regulators who remembered fen-phen all too well. It also supported the idea that lorcaserin’s selectivity for 5-HT2C over 5-HT2B genuinely spared the heart valves.

With the valve issue put to rest, the FDA approved lorcaserin in June 2012. But the agency attached a condition: the manufacturer, Arena Pharmaceuticals (which later partnered with Eisai for marketing), would need to conduct a large post-marketing cardiovascular outcomes trial to confirm the drug’s long-term safety in a high-risk population. That trial would eventually be lorcaserin’s undoing, though not for the reason anyone expected.

The Trial That Ended Everything

The post-marketing study was called CAMELLIA-TIMI 61, and it enrolled over 12,000 overweight or obese patients who already had cardiovascular disease or multiple cardiovascular risk factors. Over a median follow-up of about 3.3 years, the trial’s primary cardiovascular results were actually good news for lorcaserin. Rates of major cardiovascular events were virtually identical between the drug and placebo groups, with a hazard ratio of 0.99.⁵ The drug had passed its cardiovascular safety test.

But buried in the extended follow-up data was a different signal. When researchers looked at cancer diagnoses across the trial, they found a numerical imbalance: more cancers in the lorcaserin group than in the placebo group. The FDA reviewed these data and, in January 2020, issued a safety communication warning of a possible cancer risk. By February, the agency requested that the manufacturer voluntarily withdraw lorcaserin from the market, and Eisai complied.⁶

How Strong Was the Cancer Signal?

The cancer finding from CAMELLIA-TIMI 61 was not a dramatic spike. It was a modest numerical imbalance that reached a level the FDA considered concerning given the drug’s relatively modest weight-loss benefit. The types of cancers reported included pancreatic, lung, and colorectal cancers, though no single cancer type stood out with overwhelming statistical force. The concern was the overall pattern rather than one clear-cut association.

This subtlety has led to genuine scientific debate. A systematic review and meta-analysis that pooled data from lorcaserin’s clinical trials questioned whether the association was robust enough to warrant withdrawal, particularly given the well-known difficulties of interpreting cancer signals in trials not specifically designed to detect them.⁶ Cancer takes years or decades to develop, and a 3.3-year median follow-up is relatively short for drawing firm conclusions about carcinogenicity. The FDA’s decision reflected a precautionary stance: the drug’s benefits were modest, the cancer signal was worrying, and the risk-benefit calculus no longer favored keeping it available.

Animal Data and Possible Mechanisms

The cancer signal did not come entirely out of nowhere. Before lorcaserin was ever approved, two-year animal studies had shown that the drug caused mammary tumors in both male and female rats.⁷ The FDA’s advisory committee debated these findings at length in 2012 and ultimately concluded that the rat tumors were likely not directly relevant to humans, given differences in how the drug was metabolized across species. This judgment allowed approval to proceed, but the animal data remained a background concern throughout the drug’s market life.

More recent research has explored how serotonin signaling might connect to cancer biology in broader terms. Serotonin and its receptors can play context-dependent roles in tumor growth, potentially enhancing cell proliferation, survival, and spread through certain receptor subtypes.⁸ Work on colorectal cancer, for instance, has found that blocking certain serotonin receptors can suppress tumor growth through downstream signaling pathways involved in cell division.⁹ This does not prove that lorcaserin caused cancer through serotonin signaling. But it does highlight that the serotonin system is more entangled with cancer biology than was appreciated when the drug was first approved, and it gives researchers a plausible framework for investigating the mechanism behind the CAMELLIA-TIMI 61 findings.

Europe Never Let It In

While the FDA approved lorcaserin in 2012, European regulators took a different path. The manufacturer withdrew its European application after the European Medicines Agency indicated that approval was unlikely.¹⁰ The EMA’s concerns centered on lorcaserin’s modest efficacy relative to its safety uncertainties, including the rat tumor data. European regulators historically have been more cautious about weight-loss drugs than their American counterparts, a stance partly shaped by their own experience with rimonabant, a different anti-obesity drug that was withdrawn in Europe in 2008 over psychiatric side effects.

The European skepticism looks prescient in hindsight. Lorcaserin never reached patients in EU countries, sparing them the later withdrawal and its associated uncertainty. This difference in regulatory philosophy is worth noting because it reflects a real tension in drug approval: the FDA’s willingness to approve drugs with known risk signals in exchange for post-marketing surveillance can get treatments to patients faster, but it also means some drugs reach the market and later prove problematic.

Real-World Results Fell Short of Trial Data

Even setting aside the cancer signal, lorcaserin’s performance in actual clinical practice was underwhelming. A real-world study in primary care found that patients on lorcaserin lost considerably less weight than participants in the clinical trials. The mean weight reduction was only about 1.4 to 1.7 kilograms over six to nine months, compared with 5.8 kilograms at one year in the trials. Only about 30% of real-world patients hit the 5% weight-loss threshold, compared with roughly 47% in the controlled setting.¹¹

Several factors likely explain the gap. Clinical trials carefully select participants and provide structured lifestyle counseling, regular follow-up, and behavioral support that most real-world patients do not receive. People in everyday practice also tend to stop taking their medication sooner than trial participants do, which erodes whatever effect the drug might offer. These findings are a reminder that the headline numbers from a clinical trial represent a best-case scenario, not a guarantee of what any individual patient will experience. For lorcaserin, the real-world picture made an already modest drug look even less compelling.

Cardiovascular Outcome Trials and the Broader Regulatory Lesson

Lorcaserin’s story is inseparable from the broader evolution of how regulators evaluate obesity drugs. After the fen-phen disaster and the withdrawal of sibutramine in 2010 over cardiovascular concerns, the FDA began requiring cardiovascular outcome trials for new weight-loss medications. These large, long-running studies were designed to catch heart-related problems before they could harm large numbers of patients.¹² Ironically, CAMELLIA-TIMI 61 gave lorcaserin a clean bill of cardiovascular health while simultaneously surfacing the cancer signal that killed it.

This episode illustrates a genuine paradox of post-marketing surveillance. Requiring a large safety trial uncovered a risk that smaller pre-approval studies could never have detected. But the trial was designed to look at heart outcomes, not cancer, which means the cancer finding was an incidental observation rather than a pre-specified endpoint. That distinction matters statistically, because incidental findings in large trials can sometimes reflect random noise rather than a true drug effect. The FDA weighed this ambiguity and decided that with a drug whose benefits were modest, even an uncertain cancer signal tipped the balance toward withdrawal.

What Happened After the Withdrawal

Following the market withdrawal, patients who had been taking Belviq were advised by the FDA to stop using the drug and speak with their doctors about alternative weight management strategies. The timing coincided with a period of rapid change in obesity pharmacotherapy. Newer medications based on GLP-1 receptor agonists, and more recently dual GIP/GLP-1 agonists, were emerging with weight-loss results that far exceeded anything lorcaserin had achieved.¹³ These newer drugs routinely produce average weight loss in the range of 15% to 20% or more of body weight, dwarfing lorcaserin’s roughly 6%.

Beyond obesity treatment, lorcaserin had also attracted interest as a potential therapy for severe childhood epilepsy. A small case series evaluated it as an add-on treatment for children and young adults with severe developmental and epileptic brain disorders, finding that more than half of the patients experienced a meaningful reduction in seizure frequency, with two achieving extended seizure-free periods.¹⁴ The withdrawal of lorcaserin from the market effectively closed off this line of investigation, at least for clinical use, though research into 5-HT2C receptor activation for epilepsy continues through other compounds.

Lawsuits and Legal Fallout

The withdrawal also triggered legal action. Patients who developed pancreatic, lung, or colorectal cancer after taking Belviq began filing lawsuits against Eisai and Arena Pharmaceuticals, alleging that the companies knew or should have known about the cancer risk and failed to adequately warn patients and prescribers. The litigation centered on whether the pre-approval animal tumor data and the design of the post-marketing trial should have prompted earlier action or stronger label warnings.

These cases join a long line of product liability actions against withdrawn pharmaceuticals. For patients, the legal process is complicated by the difficulty of proving that a specific cancer was caused by a specific drug rather than by other risk factors. Cancer is common in the general population, and the incremental risk attributed to lorcaserin in the CAMELLIA-TIMI 61 data was not large in absolute terms. Whether courts find the evidence sufficient for individual claims remains an ongoing question.

Lingering Questions About Serotonin and Cancer

One of the more unsettling loose ends from the lorcaserin episode is the broader question of whether drugs that manipulate serotonin signaling carry any cancer-related risks. Serotonin is not just a brain chemical; it is active throughout the body, including in the gut, blood vessels, and immune system. Research has increasingly recognized that serotonin receptors are expressed on various tumor types and can influence tumor behavior in ways that depend on the specific receptor subtype and the tissue involved.⁸

This does not mean that commonly prescribed serotonin-related medications like SSRIs are dangerous. The pharmacology is different: SSRIs prevent the reuptake of serotonin that is already present, while lorcaserin directly activates a specific receptor. Still, the lorcaserin experience has prompted researchers to look more carefully at how serotonin receptor activation intersects with cell growth pathways, particularly in tissues where serotonin receptors are abundant. The rat mammary tumor data, the human cancer signal, and the emerging basic science on serotonin in tumors collectively suggest that this is a space where the biology is more complex than anyone assumed when the drug was designed. Understanding that complexity better could inform the development of future drugs that target the serotonin system for obesity, neurological disorders, or other conditions.

1
PubMed Central. Lorcaserin for the treatment of obesity
2
PubMed. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials
3
American Journal of Health-System Pharmacy. Lorcaserin: An investigational serotonin 2C agonist for weight loss
4
PubMed. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials
5
The New England Journal of Medicine. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
6
Obesity Reviews. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis
7
PubMed Central. CarcSeq detection of lorcaserin-induced clonal expansion of Pik3ca H1047R mutants in rat mammary tissue
8
PubMed Central. Context-dependent roles of 5-HT and its receptors in tumor growth and wound healing: Mechanisms and therapeutic implications
9
PubMed. Inhibition of HTR2B-mediated serotonin signaling in colorectal cancer suppresses tumor growth through ERK signaling
10
JAMA Internal Medicine. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
11
Family Practice. Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting
12
PubMed. Cardiovascular outcome trials in obesity: A review
13
Journal of Advances in Internal Medicine. Comparative efficacy and safety of Dual GIP/GLP1 agonists versus GLP1 receptor agonists for weight loss: A Scoping Review
14
PubMed Central. Lorcaserin therapy for severe epilepsy of childhood onset: A case series